Us fda accepts for review biohaven's new drug application (nda) filing of intranasal zavegepant for the acute treatment of migraine

If approved, zavegepant nasal spray would be the only fda-approved cgrp receptor antagonist in an intranasal formulation, giving patients a new treatment option that provides ultra-rapid pain relief in as little as 15 minutes that lasts through 48 hours after a single dose zavegepant nasal spray may provide an important alternative for patients who need a quick onset of action or those who cannot take oral treatments due to nausea and vomiting at the time of migraine onset new haven, conn. , may 23, 2022 /prnewswire/ -- biohaven pharmaceutical holding company ltd.
BHVN Ratings Summary
BHVN Quant Ranking